What's Hot

    The Future of Regulatory Technology: How RTOP and the Big 4 Are Shaping Compliance Trends

    September 12, 2023

    Elon Musk Flaunts Vast Competitive Edge — Auto Industry ‘Still Hasn’t Caught Up’ With Tesla From 10 Years Ago – Tesla (NASDAQ:TSLA)

    August 10, 2023

    Taylor Swift’s ‘Eras Tour’ Toronto Tickets Listed At $16K, Leaving Fans Aghast

    August 10, 2023
    Facebook Twitter Instagram YouTube LinkedIn TikTok Telegram
    Telegram
    InformatemiInformatemi
    Subscribe
    • Home
    • Blog
    • Contact
    InformatemiInformatemi
    Home»Investments»Analyst Expectations for KalVista Pharma’s Future – KalVista Pharma (NASDAQ:KALV)
    Investments

    Analyst Expectations for KalVista Pharma’s Future – KalVista Pharma (NASDAQ:KALV)

    Benzinga InsightsBy Benzinga InsightsApril 21, 2023Updated:April 21, 20232 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    [ad_1]

    Over the past 3 months, 4 analysts have published their opinion on KalVista Pharma KALV stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company’s business to predict how a stock will trade over the upcoming year.

    Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
    Total Ratings 3 1 0 0 0
    Last 30D 1 0 0 0 0
    1M Ago 0 0 0 0 0
    2M Ago 2 0 0 0 0
    3M Ago 0 1 0 0 0

    In the last 3 months, 4 analysts have offered 12-month price targets for KalVista Pharma. The company has an average price target of $20.0 with a high of $22.00 and a low of $16.00.

    Below is a summary of how these 4 analysts rated KalVista Pharma over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

    This current average represents a 25.93% decrease from the previous average price target of $27.00.

    Stay up to date on KalVista Pharma analyst ratings.

    If you are interested in following small-cap stock news and performance you can start by tracking it here.

    Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company’s revenue streams are.

    Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

    Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

    If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

    This article was generated by Benzinga’s automated content engine and reviewed by an editor.

    [ad_2]

    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleWhat 5 Analyst Ratings Have To Say About Ocular Therapeutix – Ocular Therapeutix (NASDAQ:OCUL)
    Next Article 18 Analysts Have This to Say About Qualtrics International – Qualtrics International (NASDAQ:XM)
    Benzinga Insights

    Related Posts

    Ted Cruz Visits Elon Musk’s SpaceX, Says ‘Maintaining American Leadership In Space Is Critical’

    August 10, 2023

    Xi Jinping Likely To ‘Bring War To The West,’ Says Prominent China Hawk: ‘He Will End Up Acquiring Taiwan By Force’

    August 10, 2023

    Will Humana Stock See Higher Levels After A 15% Rise In A Month?

    August 10, 2023
    Top Posts

    The Future of Regulatory Technology: How RTOP and the Big 4 Are Shaping Compliance Trends

    September 12, 2023

    Taylor Swift’s ‘Eras Tour’ Toronto Tickets Listed At $16K, Leaving Fans Aghast

    August 10, 2023

    Cs Disco (LAW) Q2 2023 Earnings Call Transcript

    August 10, 2023

    Subscribe to Updates

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    [wpforms id="4157" title="false"]

    Gain access to our Newsletter, SMS Alerts, and Telegram Community for FREE

    Top Insights

    The Future of Regulatory Technology: How RTOP and the Big 4 Are Shaping Compliance Trends

    September 12, 2023

    Elon Musk Flaunts Vast Competitive Edge — Auto Industry ‘Still Hasn’t Caught Up’ With Tesla From 10 Years Ago – Tesla (NASDAQ:TSLA)

    August 10, 2023

    Taylor Swift’s ‘Eras Tour’ Toronto Tickets Listed At $16K, Leaving Fans Aghast

    August 10, 2023
    Get Informed

    Subscribe to Updates

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    [wpforms id="4157" title="false"]
    Facebook Twitter Instagram YouTube LinkedIn TikTok
    • Privacy Policy
    • Disclaimer
    • SMS Squeeze
    • Sign Up
    © 2023 Informatemi

    Type above and press Enter to search. Press Esc to cancel.